Literature DB >> 28332511

Risk of acute myocardial infarction after discontinuation of antihypertensive agents: a case-control study.

F F Alharbi1, P C Souverein1, M C de Groot2, A H Maitland-van der Zee1,3, A de Boer1, O H Klungel1,4.   

Abstract

We performed a nested case-control study in a cohort of antihypertensive drug users to assess the association between discontinuation of different antihypertensive agents and the risk of acute myocardial infarction (AMI). Cases and controls were drawn from the Utrecht Cardiovascular Pharmacogenetics database. Patients who were hospitalised for their first AMI were considered cases and controls were not hospitalised for AMI. Antihypertensive users were defined as current users if the index date (date of AMI) fell within the prescribed duration or as discontinuers if this date fell outside the prescribed duration. According to the recency of discontinuation, discontinuers were divided into the following: recent discontinuers (⩽90 days), intermediate-term discontinuers (91-180 days) and long-term discontinuers (>180 days). We found that the risk of AMI was significantly increased in discontinuers, regardless of time since discontinuation, of beta-blockers (adjusted odds ratio (OR) 1.54; 95% confidence interval (CI; 1.25-1.91), P-value<0.0005), calcium channel blockers (CCBs; adjusted OR 2.25; 95% CI (1.53-3.30), P-value<0.0005) and diuretics (adjusted OR 1.76; 95% CI (1.24-2.48), P-value=0.002) compared to current users of these drugs. Moreover, the risk of AMI was significantly increased in long-term discontinuers (beta-blockers, CCBs, angiotensin-converting enzyme inhibitors and diuretics) and intermediate-term discontinuers (beta-blockers and CCBs) versus current users of these drugs. There was no difference in AMI risk between recent discontinuers of antihypertensive drugs versus current users of these drugs. In conclusion, discontinuation of antihypertensive drugs increases the risk of AMI after >90 days of discontinuation. This further underlines the importance of persistence to antihypertensive drug therapy to reduce the risk of AMI in patients with hypertension.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28332511     DOI: 10.1038/jhh.2017.1

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  24 in total

1.  Return of elevated blood pressure after withdrawal of antihypertensive drugs.

Authors: 
Journal:  Circulation       Date:  1975-06       Impact factor: 29.690

2.  Blood pressure and blood pressure variability following withdrawal of propranolol and clonidine.

Authors:  A J Neusy; J Lowenstein
Journal:  J Clin Pharmacol       Date:  1989-01       Impact factor: 3.126

Review 3.  Abrupt cessation of treatment in hypertension: consideration of clinical features, mechanisms, prevention and management of the discontinuation syndrome.

Authors:  M C Houston
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

4.  Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy.

Authors:  R R Miller; H G Olson; E A Amsterdam; D T Mason
Journal:  N Engl J Med       Date:  1975-08-28       Impact factor: 91.245

5.  Acute myocardial infarction caused by multivessel coronary spasm due to calcium channel blocker withdrawal.

Authors:  William J Kostis; William M Suh; Igor F Palacios
Journal:  Catheter Cardiovasc Interv       Date:  2011-07-15       Impact factor: 2.692

6.  Comparison of metoprolol as hydrochlorothiazide and antihypertensive agents.

Authors:  O L Pedersen
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

7.  Recruitment of participants through community pharmacies for a pharmacogenetic study of antihypertensive drug treatment.

Authors:  Diane B M A van Wieren-de Wijer; Anke-Hilse Maitland-van der Zee; Anthonius de Boer; Bruno H Ch Stricker; Abraham A Kroon; Peter W de Leeuw; O Bozkurt; Olaf H Klungel
Journal:  Pharm World Sci       Date:  2008-11-30

8.  Renin-angiotensin system polymorphisms and the association between use of angiotensin II receptor blockers or angiotensin-converting enzyme inhibitors and the risk of diabetes.

Authors:  Ozlem Bozkurt; Anthonius de Boer; Diederik E Grobbee; Abraham A Kroon; Paul Schiffers; Peter de Leeuw; Olaf H Klungel
Journal:  J Renin Angiotensin Aldosterone Syst       Date:  2009-06       Impact factor: 1.636

Review 9.  Safe discontinuation of antihypertensive therapy.

Authors:  J K Kirk; S H Johnson
Journal:  Arch Fam Med       Date:  1995-03

10.  Discontinuation of anti-hypertensive drugs increases 11-year cardiovascular mortality risk in community-dwelling elderly (the Bambuí Cohort Study of Ageing).

Authors:  Maria Lea Correa Leite; Joselia O A Firmo; Antonio Ignacio Loyola Filho; Maria Fernanda Lima-Costa
Journal:  BMC Public Health       Date:  2014-07-16       Impact factor: 3.295

View more
  3 in total

Review 1.  Beta blocker rebound phenomenon is important, but we do not know its definition, incidence or optimal prevention strategies.

Authors:  Goran Koracevic; Sladjana Micic; Milovan Stojanovic; Miloje Tomasevic; Tomislav Kostic; Radmila Velickovic Radovanovic; Dragan Lovic; Dragan Djordjevic; Miomir Randjelovic; Maja Koracevic; Zaklina Ristic
Journal:  Hypertens Res       Date:  2020-05-07       Impact factor: 3.872

2.  Effect of patient and treatment factors on persistence with antihypertensive treatment: A population-based study.

Authors:  Sara Malo; Isabel Aguilar-Palacio; Cristina Feja; María Jesús Lallana; Javier Armesto; María José Rabanaque
Journal:  PLoS One       Date:  2021-01-15       Impact factor: 3.240

Review 3.  Renin-Angiotensin System Inhibitors in Patients With COVID-19: A Meta-Analysis of Randomized Controlled Trials Led by the International Society of Hypertension.

Authors:  Sonali R Gnanenthiran; Claudio Borghi; Dylan Burger; Bruno Caramelli; Fadi Charchar; Julio A Chirinos; Jordana B Cohen; Antoine Cremer; Gian Luca Di Tanna; Alexandre Duvignaud; Daniel Freilich; D H Frank Gommans; Abraham E Gracia-Ramos; Thomas A Murray; Facundo Pelorosso; Neil R Poulter; Michael A Puskarich; Konstantinos D Rizas; Rodolfo Rothlin; Markus P Schlaich; Michael Schreinlecher; Ulrike Muscha Steckelings; Abhinav Sharma; George S Stergiou; Christopher J Tignanelli; Maciej Tomaszewski; Thomas Unger; Roland R J van Kimmenade; Richard D Wainford; Bryan Williams; Anthony Rodgers; Aletta E Schutte
Journal:  J Am Heart Assoc       Date:  2022-08-24       Impact factor: 6.106

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.